RT Journal Article
SR Electronic
T1 Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.11.20142992
DO 10.1101/2020.07.11.20142992
A1 Dejima, Hitoshi
A1 Hu, Xin
A1 Chen, Runzhe
A1 Zhang, Jiexin
A1 Fujimoto, Junya
A1 Parra, Edwin R.
A1 Haymaker, Cara
A1 Hubert, Shawna
A1 Duose, Dzifa
A1 Solis, Luisa M.
A1 Su, Dan
A1 Fukuoka, Junya
A1 Tabata, Kazuhiro
A1 Pharm, Hoa
A1 Mcgranahan, Nicholas
A1 Zhang, Baili
A1 Ye, Jie
A1 Ying, Lisha
A1 Little, Latasha
A1 Gumbs, Curtis
A1 Chow, Chi-Wan
A1 Estecio, Marcos Roberto
A1 Godoy, Myrna C.B.
A1 Antonoff, Mara B.
A1 Sepesi, Boris
A1 Pass, Harvey
A1 Behrens, Carmen
A1 Zhang, Jianhua
A1 Vaporciyan, Ara A.
A1 Heymach, John V.
A1 Scheet, Paul
A1 Lee, J. Jack
A1 Futreal, P. Andrew
A1 Reuben, Alexandre
A1 Kadara, Humam
A1 Wistuba, Ignacio
A1 Zhang, Jianjun
YR 2020
UL http://medrxiv.org/content/early/2020/08/13/2020.07.11.20142992.abstract
AB How anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. We characterized immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence. Our results demonstrated that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensely regulated immune response including down-regulation of immune-activation pathways, up-regulation of immunosuppressive pathways, higher infiltration of CD4+ T cells, lower infiltration of CD8+ T cells, decreased T cell clonality, and lower frequencies of top T cell clones in later stages. Driver mutations, HLA loss, chromosomal copy number aberrations and DNA methylation changes may collectively impinge host immune responses and facilitate immune evasion as a potential mechanism underlying outgrowth of the most fit subclones in preneoplasia into dominant clones in invasive ADC.SIGNIFICANCE There has been a drastic increase in the detection of lung nodules, many of which are lung ADC precursors. The management of these lung nodules is controversial. We discovered that immune activation and evasion have started at preneoplastic stage and lung ADC precursors may exhibit an overall better-preserved anti-tumor immune contexture suggesting therapeutic strategies reprograming the immune microenvironment in patients with lung ADC precursors prior to further immunosuppression in invasive lung cancers may be beneficial. These findings have served as the critical scientific rationale for our immunoprevention clinical trial IMPRINT-Lung (NCT03634241) recruiting individuals diagnosed with lung nodules at high risk developing invasive lung cancers.Competing Interest StatementDr. Zhang reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. The other authors declare no competing financial interests.Funding StatementThis study was supported by the MD Anderson Khalifa Scholar Award, the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629-01), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program, the MD Anderson Lung Cancer Moon Shot Program, Sabin Family Foundation Award, Duncan Family Institute Cancer Prevention Research Seed Funding Program, the Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award grant (RP160668) and the UT Lung Specialized Programs of Research Excellence Grant (P50CA70907).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Boards (IRB) at MD Anderson Cancer Center, Nagasaki University Graduate School of Biomedical Sciences and Zhejiang Cancer Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data may be found within the main manuscript or supplementary Information or available from the authors upon request.